Malaria Control Efforts Focus on Diagnostics and Next-Generation Vaccines Amid Persistent Global Challenges
カートのアイテムが多すぎます
ご購入は五十タイトルがカートに入っている場合のみです。
カートに追加できませんでした。
しばらく経ってから再度お試しください。
ウィッシュリストに追加できませんでした。
しばらく経ってから再度お試しください。
ほしい物リストの削除に失敗しました。
しばらく経ってから再度お試しください。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
-
ナレーター:
-
著者:
概要
This reflects sustained efforts to bolster diagnostics in malaria-endemic areas, where RDTs remain critical amid limited vaccine access. The International Menopause Society's March 2026 recommendations document briefly notes vaccine hesitancy as a broader issue, drawing parallels to menopause treatments but not detailing malaria specifics. At the India AI Impact Summit 2026, speakers emphasized urgency, stating, "Every year we don't have the next generation of malaria vaccines we're seeing hundreds of thousands of young children dying," per event coverage on Digital Watch Observatory.
No new vaccine trials, approvals, or deployment updates surfaced in the last 48 hours. Existing vaccines like RTS,S (Mosquirix) and R21/Matrix-M, prequalified by WHO in 2023 and 2024, continue rollout in Africa, but recent searches show no fresh data on efficacy, side effects, or expansion from sources like WHO or Gavi. Sub-Saharan health studies, such as a SciELO article on migration, list malaria among common issues like pneumonia and diarrhea, stressing primary care needs without vaccine breakthroughs.
Experts call for accelerated next-generation vaccines to curb the 600,000 annual deaths, mostly in children under five. South Africa's tender history, including past RDT and indoor spraying bids, signals resource strains in high-burden provinces. As procurement deadlines like the March 30 RFQ pass, focus shifts to implementation amid calls for innovation. (748 characters)
This content was created in partnership and with the help of Artificial Intelligence AI
まだレビューはありません